These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 2268352)
1. Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: alterations of growth factor receptor binding sites and tyrosine kinase activity. Freiss G; Rochefort H; Vignon F Biochem Biophys Res Commun; 1990 Dec; 173(3):919-26. PubMed ID: 2268352 [TBL] [Abstract][Full Text] [Related]
2. Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells. Freiss G; Vignon F Mol Endocrinol; 1994 Oct; 8(10):1389-96. PubMed ID: 7854356 [TBL] [Abstract][Full Text] [Related]
3. Cell cycle phase dependence of estrogen and epidermal growth factor (EGF) receptor expression in MCF-7 cells: implications in antiestrogen and EGF cell responsiveness. Dong XF; Berthois Y; Colomb E; Martin PM Endocrinology; 1991 Nov; 129(5):2719-28. PubMed ID: 1935801 [TBL] [Abstract][Full Text] [Related]
4. Regulation of epidermal growth factor-receptor by estrogen and antiestrogen in the human breast cancer cell line MCF-7. Berthois Y; Dong XF; Martin PM Biochem Biophys Res Commun; 1989 Feb; 159(1):126-31. PubMed ID: 2784313 [TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim. Periyasamy-Thandavan S; Takhar S; Singer A; Dohn MR; Jackson WH; Welborn AE; LeRoith D; Marrero M; Thangaraju M; Huang S; Schoenlein PV Breast Cancer Res; 2012 Mar; 14(2):R52. PubMed ID: 22429491 [TBL] [Abstract][Full Text] [Related]
6. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells. Vignon F; Lippman ME; Nawata H; Derocq D; Rochefort H Cancer Res; 1984 May; 44(5):2084-8. PubMed ID: 6713400 [TBL] [Abstract][Full Text] [Related]
7. Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1. Liang Y; Hou M; Kallab AM; Barrett JT; El Etreby F; Schoenlein PV Int J Oncol; 2003 Aug; 23(2):369-80. PubMed ID: 12851686 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of estrogen receptor, antiestrogen binding sites and calmodulin for antiestrogen resistance of two clones derived from the MCF-7 breast cancer cell line. Borras M; Jin L; Bouhoute A; Legros N; Leclercq G Biochem Pharmacol; 1994 Nov; 48(11):2015-24. PubMed ID: 7802690 [TBL] [Abstract][Full Text] [Related]
10. Extinction of insulin-like growth factor-I mitogenic signaling by antiestrogen-stimulated Fas-associated protein tyrosine phosphatase-1 in human breast cancer cells. Freiss G; Puech C; Vignon F Mol Endocrinol; 1998 Apr; 12(4):568-79. PubMed ID: 9544992 [TBL] [Abstract][Full Text] [Related]
11. Antiestrogens prevent the stimulatory effects of L-triiodothyronine on cell proliferation. Zhou-Li F; Albaladejo V; Joly-Pharaboz MO; Nicolas B; Andre J Endocrinology; 1992 Mar; 130(3):1145-52. PubMed ID: 1537281 [TBL] [Abstract][Full Text] [Related]
12. The effect of droloxifene on the insulin-like growth factor-I-stimulated growth of breast cancer cells. Kawamura I; Lacey E; Mizota T; Tsujimoto S; Nishigaki F; Manda T; Shimomura K Anticancer Res; 1994; 14(2A):427-31. PubMed ID: 8017842 [TBL] [Abstract][Full Text] [Related]
13. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Guvakova MA; Surmacz E Cancer Res; 1997 Jul; 57(13):2606-10. PubMed ID: 9205064 [TBL] [Abstract][Full Text] [Related]
14. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799 [TBL] [Abstract][Full Text] [Related]
15. Physicochemical and genetic evidence for specific antiestrogen binding sites. Faye JC; Jozan S; Redeuilh G; Baulieu EE; Bayard F Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3158-62. PubMed ID: 6574477 [TBL] [Abstract][Full Text] [Related]
16. Accumulation of a non-binding form of estrogen receptor in MCF-7 cells under hydroxytamoxifen treatment. Leclercq G; Legros N; Piccart MJ J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):545-52. PubMed ID: 1562525 [TBL] [Abstract][Full Text] [Related]
17. Synthetic antiestrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3',5'-monophosphate in MCF7 cells. Chalbos D; Philips A; Galtier F; Rochefort H Endocrinology; 1993 Aug; 133(2):571-6. PubMed ID: 8344199 [TBL] [Abstract][Full Text] [Related]
18. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Catherino WH; Wolf DM; Jordan VC Mol Endocrinol; 1995 Aug; 9(8):1053-63. PubMed ID: 7476979 [TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen. Taylor CM; Blanchard B; Zava DT Cancer Res; 1984 Apr; 44(4):1409-14. PubMed ID: 6704959 [TBL] [Abstract][Full Text] [Related]
20. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. Gundimeda U; Chen ZH; Gopalakrishna R J Biol Chem; 1996 Jun; 271(23):13504-14. PubMed ID: 8662863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]